March 24, 2019
1 min read
Save

Patients treated with aflibercept experienced greater improvements in NPDR

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

W. Lloyd Clark

FORT LAUDERDALE, Fla. — The proportion of patients with a 2 or more-step improvement in non-proliferative diabetic retinopathy scores was significantly greater when treated with aflibercept compared to a sham, according to a speaker here.

“PANORAMA is the first large, prospective trial of high risk, non-proliferative diabetic retinopathy patients since the Early Treatment Diabetic Retinopathy Study,” W. Lloyd Clark, MD, said at the Retina World Congress.

Clark presented the 52-week results of the PANORAMA study, a phase 3, double-masked study that evaluated the efficacy and safety of intravitreal aflibercept injections in patients with moderately severe to severe non-proliferative diabetic retinopathy.

The study included 402 randomized total participants, with 135 being treated with 2 mg of aflibercept every 16 weeks, 134 being treated with 2 mg of aflibercept every 8 weeks, and 133 in in a sham control.

“Vision threatening complications occurred in a substantially greater proportion of sham patients and no safety signals with aflibercept were identified,” he said.

The primary endpoint of the study was the proportion of patients with a 2 or more-step improvement from baseline in diabetic retinopathy severity scores at week 52. Clark noted 65.2% of patients treated with aflibercept every 16 weeks and 79.9% of patients treated every 8 weeks improved 2 or more-steps compared with just 15% of sham patients.

“When pooled with center-involved diabetic macular edema, 40% of eyes in the sham group developed a complication within 1 year of the PANORAMA study. That compares very favorably to the active treatment groups with an approximately 75% reduction in rates of complications in eyes treated actively with aflibercept regardless of dosing,” he said. – by Robert Linnehan

 

Reference: Clark WL. The Value of Treating Non-proliferative Diabetic Retinopathy. Presented at: Retina World Congress; March 21 to 24, 2019; Fort Lauderdale, Fla.

Disclosure: Clark reports he is a speaker, consultant, and receives grant support from Regeneron and Genentech/Roche. He reports receiving grant support from Santen.